MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company seeking to develop and commercialize off-the-shelf, allogeneic, invariant natural killer T (‘iNKT) cell therapies to treat cancer and other immune-mediated diseases.
- Sector(s): Healthcare
- Industry: Biotechnology
- Full Time Employees: 33
- HQ: New York, New York
- https://minktherapeutics.com
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Technology
iNKT cells are a distinct type of T cells, which in response to lipid antigenic stimulation, rapidly produce within minutes, large amounts of cytokines that can influence other immune cells. These are important immunoregulatory cells though comprising less than 1% of peripheral blood mononuclear cells (‘PBMCs) in the human blood pool. With their durable memory responses and rapid cytolytic features, iNKT cells have been shown to improve microbial and tumor immunity, while suppressing autoimmune disease and promoting tolerance. iNKT cell-derived cytokines and chemokines can modulate several other cell types, including NK cells, conventional CD4+ and CD
No comments:
Post a Comment